Clinical Trial Update: Comparison of 177Lu-PSMA-617 and 225Ac-PSMA-617 [Phase 1]

View source ↗

Summary

Phase 1 trial comparing Lutetium-177 PSMA-617 with Actinium-225 PSMA-617 in prostate cancer is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Prostate Cancer

Drugs mentioned

• 177Lu-PSMA-617 (Lutetium-177 PSMA-617)
• 225Ac-PSMA-617 (PSMA-617 radiolabeled with Actinium-225)

Snippet

Sponsor: Thomas Hope | Conditions: Prostate Cancer, Prostate Cancer (Diagnosis) | Phase 1 | Status: RECRUITING